In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A)
- PMID: 8494369
- PMCID: PMC187747
- DOI: 10.1128/AAC.37.4.741
In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A)
Abstract
MDL 62,879 (GE2270 A) is a new peptide antibiotic that inhibits protein synthesis through an interaction with elongation factor Tu. MDL 62,879 was very active against gram-positive clinical isolates, particularly staphylococci and enterococci, for which MICs for 90% of isolates were < or = 0.13 micrograms/ml. It was equally active against isolates resistant to beta-lactams, erythromycin, gentamicin, and glycopeptides. It also had activity against Mycobacterium tuberculosis. MDL 62,879 had moderate bactericidal activity against staphylococci.
Similar articles
-
In vitro activity of MDL 62,879 against gram-positive bacteria and Bacteroides species.Eur J Clin Microbiol Infect Dis. 1995 Dec;14(12):1105-8. doi: 10.1007/BF01590950. Eur J Clin Microbiol Infect Dis. 1995. PMID: 8681991
-
In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria.Antimicrob Agents Chemother. 1993 Apr;37(4):746-9. doi: 10.1128/AAC.37.4.746. Antimicrob Agents Chemother. 1993. PMID: 8494370 Free PMC article.
-
In vitro antimicrobial activity of the thiazolyl peptide antibiotic MDL 62,879 (GE2270 A).Chemotherapy. 1997 Jul-Aug;43(4):254-63. doi: 10.1159/000239576. Chemotherapy. 1997. PMID: 9209782
-
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.Diagn Microbiol Infect Dis. 1999 Feb;33(2):101-12. doi: 10.1016/s0732-8893(98)00108-4. Diagn Microbiol Infect Dis. 1999. PMID: 10091033 Review.
-
In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.J Antimicrob Chemother. 1997 May;39 Suppl A:15-21. doi: 10.1093/jac/39.suppl_1.15. J Antimicrob Chemother. 1997. PMID: 9511057 Review.
Cited by
-
In vitro and in vivo activities of novel, semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu.Antimicrob Agents Chemother. 2011 Nov;55(11):5277-83. doi: 10.1128/AAC.00582-11. Epub 2011 Aug 8. Antimicrob Agents Chemother. 2011. PMID: 21825297 Free PMC article.
-
Increasing problems in the therapy of enterococcal infections.Eur J Clin Microbiol Infect Dis. 1993 Jun;12(6):409-12. doi: 10.1007/BF01967433. Eur J Clin Microbiol Infect Dis. 1993. PMID: 8359159 No abstract available.
-
In vitro activity of MDL 62,879 against gram-positive bacteria and Bacteroides species.Eur J Clin Microbiol Infect Dis. 1995 Dec;14(12):1105-8. doi: 10.1007/BF01590950. Eur J Clin Microbiol Infect Dis. 1995. PMID: 8681991
-
Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.Antimicrob Agents Chemother. 2012 May;56(5):2493-503. doi: 10.1128/AAC.06305-11. Epub 2012 Jan 30. Antimicrob Agents Chemother. 2012. PMID: 22290948 Free PMC article.
-
Advances in MRSA drug discovery: where are we and where do we need to be?Expert Opin Drug Discov. 2013 Sep;8(9):1095-116. doi: 10.1517/17460441.2013.807246. Epub 2013 Jul 6. Expert Opin Drug Discov. 2013. PMID: 23829425 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical